Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
5 hedge funds and large institutions have $3.91K invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 23 closing their positions.
82% less funds holding
Funds holding: 28 → 5 (-23)
98% less capital invested
Capital invested by funds: $249K → $3.91K (-$245K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 23
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$75.1K |
| 2 |
Walleye Capital
New York
|
-$46.4K |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
-$43.8K |
| 4 |
JRCM
Jones Road Capital Management
New York
|
-$16.7K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$11.3K |
DNA.WS Hedge Fund Activity: Q3 2024 in Review
5 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q3 2024, worth a combined $3.91K — down 98% from $249K a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of DNA.WS and 0 opened new positions — a net loss of 23 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Cowen and Company, exiting entirely with an estimated $75.1K sold.
- 5 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q3 2024, down from 28 in Q2 2024.
- Funds reported $3.91K of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q3 2024, down 98% quarter-over-quarter.
- 0 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q3 2024 and 23 closed out, a net change of -23 holders.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q3 2024 was Cowen and Company, an estimated $75.1K sold.
Based on aggregated 13F filings for Q3 2024.